NICE(UK) positive for Calquence + bendamustine and rituximab for untreated mantle cell lymphoma – AstraZeneca

NICE(UK): Acalabrutinib plus bendamustine and rituximab can be used, within its marketing authorisation, as an option for untreated mantle cell lymphoma in adults who are not eligible for an autologous stem cell transplant.
Acalabrutinib plus bendamustine and rituximab can only be used if the company provides it according to the commercial arrangement.

Why the committee made this recommendation: Usual treatment for untreated mantle cell lymphoma in adults who cannot have an autologous stem cell transplant is bendamustine plus rituximab. Clinical trial evidence shows that acalabrutinib plus bendamustine and rituximab increases how long people have before their condition gets worse compared with usual treatment. The cost-effectiveness estimates are within the range that NICE considers an acceptable use of NHS resources.

So, acalabrutinib plus bendamustine and rituximab can be used.